Mitochondrial calcium deposits in soft tissues

Mitochondrial calcium deposits in soft tissues represent a pathological accumulation of calcium phosphate minerals, typically in the form of hydroxyapatite, within the mitochondrial matrix of non-osseous cells. This process is often initiated by mitochondrial calcium overload, where the organelle's capacity to buffer intracellular calcium is overwhelmed, leading to crystal nucleation and subsequent organelle dysfunction (PMID: 28807910). These deposits are characteristic of conditions involving systemic mineral dysregulation, such as chronic kidney disease, or localized tissue damage, where they contribute to cell death and tissue hardening (PMID: 15591003). While the deposits themselves are physical manifestations of disease rather than discrete molecular targets like receptors or enzymes, they serve as critical focal points for therapeutic intervention aimed at preventing vascular and visceral calcification. Current pharmacological strategies focus on inhibiting crystal growth using agents like sodium thiosulfate or modulating systemic mineral metabolism via calcimimetics and phosphate binders (PMID: 30104279). Research into the Mitochondrial Calcium Uniporter (MCU) also suggests that modulating calcium entry into the mitochondria may prevent the formation of these deposits in high-risk patients (PMID: 23913386).

Other names

Mitochondrial calcificationSoft tissue calcificationMetastatic calcificationDystrophic calcificationHydroxyapatite depositsEctopic calcification

Inhibition of hydroxyapatite crystal nucleation and growth; chelation of calcium ions to increase solubility; reduction of systemic phosphate and calcium levels to prevent precipitation.